Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a report issued on Saturday.

Several other research firms also recently commented on ALNY. Wells Fargo & Company decreased their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 20th. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Jefferies Financial Group reiterated a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Chardan Capital lowered their price target on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Finally, Truist Financial reduced their price objective on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $468.84.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $306.66 on Friday. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The firm has a market capitalization of $40.67 billion, a price-to-earnings ratio of 179.33 and a beta of 0.36. The stock’s 50 day moving average price is $334.13 and its two-hundred day moving average price is $403.74. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the prior year, the firm posted ($0.65) earnings per share. The business’s revenue was up 84.9% compared to the same quarter last year. On average, analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the completion of the sale, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. The trade was a 10.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the sale, the executive vice president directly owned 21,264 shares of the company’s stock, valued at $7,874,697.12. This represents a 9.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 in the last three months. 1.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Groupama Asset Managment increased its stake in Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the period. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $895,816,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after purchasing an additional 1,185,909 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $369,943,000. Finally, Holocene Advisors LP bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $194,616,000. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.